Cosciens Biopharma Inc. ( (CSCIF) ) has released its Q3 earnings. Here is a breakdown of the information Cosciens Biopharma Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
COSCIENS Biopharma Inc., a life science company specializing in natural ingredients and pharmaceutical solutions, has reported its financial results for the third quarter of 2025, highlighting significant strategic initiatives. The company, which focuses on the development and commercialization of plant-based active ingredients and diagnostic products, has recently delisted from Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX).
In the third quarter of 2025, COSCIENS reported a consolidated net loss of $1.8 million, a notable improvement from the $5.8 million loss in the same period of 2024. This reduction in net loss is attributed to the company’s restructuring efforts, which have resulted in a 59% decrease in operating expenses compared to the previous year. The company also reported a decrease in total revenue to $1.5 million, down from $1.9 million in the third quarter of 2024, primarily due to reduced sales of key products.
Key strategic moves include the suspension of the Juvente Cosmeceuticals line due to limited success in e-commerce channels and a focus on expanding the active ingredients business into new markets such as food and beverage, dermatology, and pharmaceuticals. Additionally, COSCIENS is exploring further development opportunities for its pharmaceutical product Macrilen, despite challenges in achieving full pediatric approval in the U.S. market.
Looking forward, COSCIENS aims to enhance its operational efficiency and competitiveness by continuing to streamline its cost structure and exploring new market opportunities. The company is also seeking to expand its presence in the U.S. market through potential partnerships and licensing opportunities, while evaluating the commercialization potential of its proprietary PGX technology.